Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy

Leukemia and Lymphoma

Volumn 45, Issue 10, 2004, Pages 2085-2092

  Visco, Carlo ^a,d   Vassilakopoulos, Theodoros P ^e   Kliche, Kay Oliver ^a   Nadali, Gianpaolo ^d   Viviani, Simonetta ^c   Bonfante, Valeria ^c   Medeiros, L Jeffrey ^a   Notti, P ^c   Rassidakis, George Z ^a   Peethambaram, Prema ^b   Wilder, Richard ^a   Witzig, Thomas ^b   Gianni, Massimo ^c   Bonadonna, Gianni ^c   Pizzolo, Giovanni ^d   Pangalis, Gerassimos A ^e   Cabanillas, Fernando ^a   Sarris, Andreas H ^a,f  

^a UNIVERSITY OF TEXAS   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF ATHENS   (Greece)

^f HYGEIA HOSPITAL   (Greece)

Author keywords

Hodgkin's disease; Interleukin 10; Prognostic factors; Radiotherapy

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 10;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SYMPTOMATOLOGY; TUMOR BIOPSY;

ADOLESCENT; ADULT; BETA 2-GLYCOPROTEIN I; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 4544339987     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001712234     Document Type: Article

References (57)

1. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. and Tubiana, M. (1971) "Report of the Committee on Hodgkin's Disease Staging Classification", Cancer Research, 31, 1860-1861.
2. Hagemeister, F.B., Fuller, L.M., Sullivan, J.A., Johnston, D., North, L., Butler, J.J., et al. (1982) "Treatment of patients with stages I and II nonmediastinal Hodgkin's disease", Cancer, 50, 2307-2313.
3. Leslie, N.T., Mauch, P.M. and Hellman, S. (1985) "Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency", Cancer, 55, 2072-2078.
4. Sutcliffe, S.B., Gospodarowicz, M.K., Bergsagel, D.E., Bush, R.S., Alison, R.E., Bean, H.A., et al. (1985) "Prognostic groups for management of localized Hodgkin's disease", Journal of Clinical Oncology, 3, 393-401.
5. Cornbleet, M.A., Vitolo, U., Ultmann, J.E., Golomb, H.M., Oleske, D., Griem, M.L., et al. (1985) "Pathologic stages IA and IIA Hodgkin's disease: Results of treatment with radiotherapy alone (1968-1980) ", Journal of Clinical Oncology, 3, 758-768.
6. Carde, P., Burgers, J.M.V., Henry-Amar, M., Hayat, M., Sizoo, W., Van der Schueren, E., et al. (1988) "Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors", Journal of Clinical Oncology, 6, 239-252.
7. Farah, R., Ultmann, J., Griem, M., Golomb, H., Kalokhe, U., Desser, R., et al. (1988) "Extended mantle radiation therapy for pathologic Stage I and II Hodgkin's disease", Journal of Clinical Oncology, 6, 1047-1052.
8. Backstrand, K.H., Ng, A.K., Takvorian, R.W., Jones, E.L., Fisher, D.C., Molnar-Griffin, B.J., et al. (2001) "Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease", Journal of Clinical Oncology, 19, 736-741.
9. Mauch, P., Tarbell, N., Weinstein, H., Silver, B., Goffman, T., Osteen, R., et al. (1988) "Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation", Journal of Clinical Oncology, 6, 1576-1583.
10. Gospodarowicz, M.K., Sutcliffe, S.B., Bergsagel, D.E. and Chua, T. (1992) "Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group", European Journal of Cancer, 11, 1841-1846.
11. Carde, P., Hagenbeek, A., Hayat, M., Monconduit, M., Thomas, J., Burgers, M.J.V., et al. (1993) "Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group", Journal of Clinical Oncology, 11, 2258-2272.
12. Noordijk, E.M., Carde, P., Mandard, A.M., Mellink, W.A., Monconduit, M., Eghbali, H., et al. (1994) "Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease", Annals of Oncology, 5(Suppl.2), 107-112.
13. Duhmke, E., Franklin, J., Pfreundschuh, M., Sehlen, S., Willich, N., Ruhl, U., et al. (2001) "Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone", Journal of Clinical Oncology, 19, 2905-2914.
14. Haybittle, J.L., Hayhoe, F.G., Easterling, M.J., Jelliffe, A.M., Bennett, M.H., Vaughan-Hudson, G., et al. (1985) "Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index", Lancet, 1, 967-972.
15. Horwich, A., Easton, D., Nogueira-Costa, R., Liew, K.H., Colman, M. and Peckham, M.J. (1986) "An analysis of prognostic factors in early stage Hodgkin's disease", Radiotherapy Oncology, 7, 95-106.
16. Tubiana, M., Henry-Amar, M., Carde, P., Burgers, J.M., Hayat, M., Van der Schueren, E., et al. (1989) "Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987", Blood, 73, 47-56.
17. Cosset, J.M., Ferme, C., Henry-Amar, M. and Carde, P. (1999) "The role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives", Cancer Radiotherapy, 3, 112-118.
18. Verger, E., Easton, D., Brada, M., Duchesne, G. and Horwich, A. (1988) "Radiotherapy results in laparotomy-staged Hodgkin's disease", Clinical Radiology, 39, 428-431.
19. Tubiana, M., Henry-Amar, M., Hayat, M., Burgers, M., Qasim, M., Somers, R., et al. (1984) "The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy", International Journal of Radiation Oncology Biology Physics, 10, 197-210.
20. Crnkovich, M.J., Leopold, K., Hoppe, R.T. and Mauch, P. (1987) "Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy", Journal of Clinical Oncology, 5, 1041-1049.
21. Specht, L., Nordentoft, A.M., Cold, S., Toffner Clausen, N. and Nissen, N. (1988) "Tumor burden as the most important prognostic factor in early-stage Hodgkin's disease: relations to other prognostic factors and implications for choice of treatment", Cancer, 61, 1719-1727.
22. Henry-Amar, M., Meerwaldt, J., Carde, P., Noordijk, E.M., Thomas, J., Eghbali, H., et al. (2001) "The EORTC treatment strategy in Hodgkin's lymphoma (HL): A 4-decade experience", Leukemia and Lymphoma, 42(Suppl. 2), 54.
23. Hasenclever, D. and Diehl, V. (1998) "A prognostic score for advanced Hodgkin's disease", New England Journal of Medicine, 339, 1506-1514.
24. Franklin, J., Paulus, U., Lieberz, D., Breuer, K., Tesch, H. and Diehl, V. (2000) "Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients?", Annals of Oncology, 11, 617-623.
25. Nadali, G., Tavecchia, L., Zanolin, E., Bonfante, V., Viviani, S., Camerini, E., et al. (1998) "Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome", Blood, 91, 3011-3016.
26. Axdorph, U., Sjoberg, J., Grimfors, G., Landgren, O., Porwit-MacDonald, A. and Björkholm, M. (2000) "Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease", Annals of Oncology, 11, 1405-1411.
27. Enblad, G., Sundstrom, C., Gronowitz, S. and Glimelius, B. (1995) "Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis" , Annals of Oncology, 6, 65-70.
28. Sarris, A.H., Kliche, K.O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., et al. (1999) "Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival", Annals of Oncology, 10, 433-440.
29. Vassilakopoulos, T.P., Nadali, G., Angelopoulou, M.K., Siakantaris, M.P., Dimopoulou, M.N., Kontopidou, F.N., et al. (2001) "Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma", Haematologica, 86, 274-281.
30. Viviani, S., Notti, P., Bonfante, V., Verderio, P., Valagussa, P. and Bonadonna, G. (2000) "Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience", Medical Oncology, 17, 59-63.
31. Bohlen, H., Kessler, M., Sextro, M., Diehl, V. and Tesch, H. (2000) "Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease", Annals of Hematology, 79, 110-113.
32. Salgami, E.V., Efstathiou, S.P., Vlachakis, V., Sekara, E.V., Syrigos, K.N. and Roussou, P.P. (2002) "High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma", Haematologia (Budap), 32, 377-387.
33. Rassidakis, G.Z., Medeiros, L.J., Vassilakopoulos, T.P., Viviani, S., Bonfante, V., Nadali, G., et al. (2002) "Bcl-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens", Blood, 100, 3935-3941.
34. Garcia, J.F., Camacho, F.I., Morente, M., Fraga, M., Montalban, C., Alvaro, T., et al. (2003) "Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays", Blood, 101, 681-689.
35. Rassidakis, G.Z., Medeiros, L.J., McDonnell, T.J., Viviani, S., Bonfante, V., Nadali, G., et al. (2002) "Bax expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome", Clinical Cancer Research, 8, 488-493.
36. Dukers, D.F., Meijer, C.J.L.M., ten Berge, R.L., Vos, W., Ossenkoppele, G.J. and Oudejans, J.J. (2002) "High numbers of active caspase 3-positive Reed Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin's disease predict favorable clinical outcome", Blood, 100, 36-42.
37. Rassidakis, G.Z., Medeiros, L.J., Drakos, E., Vassilakopoulos, T.P., Viviani, S., Bonfante, V., et al. (2002) "Activated caspase-3 in Hodgkin and Reed-Sternberg cells (HRS) predicts a poorer prognosis in patients with classical Hodgkin's disease (HD) treated with ABVD or equivalent regimens", Blood, 100(11), 349a (Abstract).
38. Weber-Nordt, R.M., Henschler, R., Schott, E., Wehinger, J., Behringer, D., Mertelsmann, R., et al. (1996) "Interleukin-10 increases Bcl-2 expression and survival in primary human CD34 + hematopoietic progenitor cells", Blood, 88, 2549-2558.
39. Taga, K., Cherney, B. and Tosato, G. (1993) "IL-10 inhibits apoptotic cell death in human T cells starved of IL-2", International Immunology, 5, 1599-1608.
40. Brunetti, M., Martelli, N., Colasante, A., Piantelli, M., Musiani, P. and Aiello, F.B. (1995) "Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes", Blood, 86, 4199-4205.
41. Ohshima, K., Suzumiya, J., Akamatu, M., Takeshita, M. and Kikuchi, M. (1995) "Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4 + and CD8 + T lymphocytes", International Journal Cancer, 62, 5-10.
42. Herbst, H., Foss, H.D., Samol, J., Araujo, I., Klotzbach, H., Krause, H., et al. (1996) "Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease", Blood, 87, 2918-2929.
43. Rueda, A., Alba, E., Ribelles, N., Sevilla, I., Ruiz, I. and Miramon, J. (1997) "Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study", Journal of Clinical Oncology, 15, 1118-1122.
44. Straus, D.J., Yahalom, J., Zelenetz, A.D., Qin, J., Myers, J., Moskowitz, C.H., et al. (2001) "Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non bulky Hodgkin's disease", Blood, 98, 769a [Abstract].
45. Rappaport, H., Berard, C.W., Butler, J.J., Dorfman, R.F., Lukes, R.J. and Thomas, L.B. (1971) "Report of the committee on histopathological criteria contributing to staging of Hodgkin's disease", Cancer Research, 31, 1864-1865.
46. Stein, H., Mann, R., Delsol, G., Poppema, S., Pileri, S., Jaffe, E.S., et al. (2001) Classical Hodgkin lymphoma. In: Tumors of the haematopoietic and lymphoid tissues. Pathology and Genetics. World Health Organization Classification of Tumors, edited by E. Jaffe, N. Harris, H. Stein and J. Vardiman. Pp 244-253. Lyon, France: IARC Press.
47. Sarris, A.H. (1997) "Prognostic factors in early-stage Hodgkin's disease", Journal of Clinical Oncology, 15, 411-412.
48. 2-microglobulin in patients with Hodgkin's lymphoma", Haematologica, 87, 701-708.
49. Kaplan, E. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", Journal of American Statistical Association, 53, 457-481.
50. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., et al. (1977) "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples", Br. J. Cancer, 35, 1-39.
51. Cox, D.R. (1972) "Regression models and life tables (with discussion)", Journal Royal Statistical Society, 34, 187-220.
52. Angelopoulou, M.K., Vassilakopoulos, T.P., Siakantaris, M.P., Kontopidou, F.N., Boussiotis, V.A., Papavassiliou, C., et al. (2000) "EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease", Leukemia and Lymphoma, 37, 131-143.
53. Santoro, A., Bonfante, V., Viviani, S., Devizzi, L., Zanini, M., Soncini, F., et al. (1996) "Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD)", Proceedings of the American Society of Clinical Oncology, 15, 415 (Abstract).
54. Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Kontopidou, F.N., Dimopoulou, M.N., Kokoris, S.I., et al. (2004) "Combination chemotherapy plus low dose involved field radiation for early clinical stage Hodgkin's lymphoma", International Journal of Radiation Oncology Biology Physics (in press).
55. Ruiz-Argüelles, G.J., Gomez-Almaguer, D. and Apreza-Molina, M.G. (1997) "Chemotherapy alone may be an efficient alternative in the treatment of early stage Hodgkin's disease if optimal radiotherapy is not available", Leukemia and Lymphoma, 27, 179-183.
56. Dukers, D.F., Jaspars, L.H., Vos, W., Oudejans, J.J., Hayes, D., Cillessen, S., et al. (2000) "Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease", Journal of Pathology, 190, 143-149.
57. Rassidakis, G.Z., Medeiros, L.J., Nadali, G., Viviani, S., Bonfante, V., Vassilakopoulos, T.P., et al. (2001) "Expression of interleukin-10 (IL-10) in Hodgkin's disease (HD): Pathologic and clinical associations", Blood, 98(11-part 1), 599a (Abstract).